INVESTOR ALERT: Ultragenyx Pharmaceutical Inc. (RARE) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP Announces
RARESAN DIEGO, Feb. 5, 2026 /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP announces that the Ultragenyx class action lawsuit seeks to represent purchasers or acquirers of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) common stock between August 3, 2023 and December 26,...
Investor Notice: Shareholder Rights Law Firm Robbins LLP Informs Investors of the Ultragenyx Pharmaceutical Inc. Securities Class Action Lawsuit
RARESAN DIEGO--(BUSINESS WIRE)---- $RARE #Health--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) common stock between August 3, 2023 and December 26, 2025. Ultragenyx is a biopharmaceutical company focused on rare and ultrarare genetic disorders. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The Allegations: Robbins LLP is Investigat
Ultragenyx to Present at the 44th Annual J.P. Morgan Healthcare Conference
RARENOVATO, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced that Emil D. Kakkis, M.D., Ph.D., the company's chief executive officer and president, will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026, at 10:30 AM PT.
Ultragenyx to Participate at Investor Conferences in September
RARE(NASDAQ:RARE) NOVATO, Calif., Aug. 29, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced participation in three upcoming investor conferences.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE
RARENEW YORK, Aug. 27, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Ultragenyx Pharmaceutical Inc. ("Ultragenyx" or the "Company") (NASDAQ: RARE). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
RARENOVATO, Calif., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today reported the grant of 113,572 restricted stock units of the company’s common stock to 33 newly hired non-executive officers of the company. The awards were approved by the compensation committee of the company’s board of directors and granted under the Ultragenyx Employment Inducement Plan, with a grant date of August 16, 2025, as an inducement material to the new employees entering into employment with Ultragenyx in accordance with Nasdaq Listing Rule 5635(c)(4).
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE
RARENEW YORK, Aug. 11, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Ultragenyx Pharmaceutical Inc. ("Ultragenyx" or the "Company") (NASDAQ: RARE). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
What 4 Analyst Ratings Have To Say About Ultragenyx Pharmaceutical
RAREAnalyst Bullish On Ultragenyx, Poised For Growth With Six Drug Approvals Expected By 2028
RAREUltragenyx sees rising revenue and analyst support as key drug launch approaches, with potential profitability projected for 2027.
William Blair Initiates Coverage On Ultragenyx Pharmaceutical with Outperform Rating, Announces Price Target of $65
RAREMorgan Stanley Maintains Overweight on Ultragenyx Pharmaceutical, Raises Price Target to $65
RAREUltragenyx Pharmaceutical Affirms FY2025 Sales Guidance of $640.00M-$670.00M vs $655.02M Est
RAREUltragenyx Pharmaceutical Q1 EPS $(1.57) Beats $(1.59) Estimate, Sales $139.29M Miss $143.83M Estimate
RAREUltragenyx Pharmaceutical's Earnings: A Preview
RAREUltragenyx Stays On JPMorgan's Focus List As Analyst Highlights Strong Long-Term Positioning
RAREJP Morgan sees strong upside for Ultragenyx, citing setrusumab trial progress and pipeline growth, raising the price target to $117.
Demystifying Ultragenyx Pharmaceutical: Insights From 10 Analyst Reviews
RAREPiper Sandler Maintains Overweight on Ultragenyx Pharmaceutical, Lowers Price Target to $115
RARECantor Fitzgerald Reiterates Overweight on Ultragenyx Pharmaceutical, Maintains $118 Price Target
RAREHC Wainwright & Co. Reiterates Buy on Ultragenyx Pharmaceutical, Maintains $95 Price Target
RAREUltragenyx Pharmaceutical Announces FDA Acceptance And Priority Review Of The BLA For UX111 AAV Gene Therapy To Treat Sanfilippo Syndrome Type A
RARECanaccord Genuity Maintains Buy on Ultragenyx Pharmaceutical, Raises Price Target to $136
RAREBreaking Down Ultragenyx Pharmaceutical: 7 Analysts Share Their Views
RAREHC Wainwright & Co. Reiterates Buy on Ultragenyx Pharmaceutical, Maintains $95 Price Target
RAREUltragenyx Pharmaceutical Sees FY25 Revenue $640M-$670M Vs $652.946M Est.
RAREUltragenyx Pharmaceutical Q4 2024 GAAP EPS $(1.39) Misses $(1.29) Estimate, Sales $164.877 Miss $155.393M Estimate
RAREUltragenyx's Multiple Commercial Assets And Candidates Impress Analyst; Sees Solid Upside
RAREUltragenyx forecasts 2024 revenue above estimates, highlights confidence in setrusumab trial progress, and outlines plans for regulatory filings in 2025.
Piper Sandler Maintains Overweight on Ultragenyx Pharmaceutical, Raises Price Target to $140
RAREWedbush Reiterates Neutral on Ultragenyx Pharmaceutical, Maintains $48 Price Target
RAREUltragenyx Reported Sunday Preliminary 2024 Total Revenue Of $555M To $560M, Exceeding Top End Of Guidance; 2025 Expected Total Revenue Guidance Of $640M To $670M
RAREHC Wainwright & Co. Reiterates Buy on Ultragenyx Pharmaceutical, Maintains $95 Price Target
RAREExpert Outlook: Ultragenyx Pharmaceutical Through The Eyes Of 11 Analysts
RAREWells Fargo Maintains Overweight on Ultragenyx Pharmaceutical, Raises Price Target to $88
RAREUltragenyx Doses First Patient In Pivotal Phase 3 Aspire Study Evaluating GTX-102 In Angelman Syndrome
RAREUltragenyx Submits Biologics License Application To FDA For UX111 AAV Gene Therapy Seeking Accelerated Approval For Sanfilippo Syndrome Type A Treatment
RARECanaccord Genuity Maintains Buy on Ultragenyx Pharmaceutical, Raises Price Target to $121
RARERBC Capital Reiterates Outperform on Ultragenyx Pharmaceutical, Maintains $77 Price Target
RARECantor Fitzgerald Reiterates Overweight on Ultragenyx Pharmaceutical, Maintains $116 Price Target
RAREEvaluating Ultragenyx Pharmaceutical: Insights From 7 Financial Analysts
RAREHC Wainwright & Co. Maintains Buy on Ultragenyx Pharmaceutical, Raises Price Target to $95
RAREUltragenyx Pharmaceutical Sees FY24 Revenue $530M-$550M Vs $536.8M Est
RAREUltragenyx Pharmaceutical Q3 2024 GAAP EPS $(1.40) Beats $(1.53) Estimate, Sales $139.494M Beat $135.794M Estimate
RAREA Look Ahead: Ultragenyx Pharmaceutical's Earnings Forecast
RAREUltragenyx Faces Lawsuit Over Alleged Unjust Use of Henrietta Lacks' Cells
RAREThe estate of Henrietta Lacks can proceed with a lawsuit against Ultragenyx Pharmaceutical over the use of HeLa cells taken without her consent in the 1950s. A Maryland federal court ruled against Ultragenyx's motion to dismiss, allowing the case to continue.
Ultragenyx Pharmaceutical's Earnings Outlook
RAREUltragenyx Pharmaceutical (NASDAQ:RARE) is set to give its latest quarterly earnings report on Thursday, 2022-05-05. Here's what investors need to know before the announcement.
Analysts estimate that Ultragenyx Pharmaceutical will report an earnings per share (EPS) of $-1.76.
